Packaged Device Or Kit Patents (Class 435/810)
-
Patent number: 7419806Abstract: Mycoplasma hyopneumoniae polypeptides and nucleic acids, as well as nucleic acid expression vectors and host cells containing nucleic acid vectors are provided. In addition, compositions containing M. hyopneumoniae polypeptides and nucleic acids are provided for use in methods of treating swine to prevent enzootic pneumonia. Furthermore, the invention provides diagnostic tests for the detecting of M. hyopneumoniae infection in swine herds.Type: GrantFiled: June 27, 2003Date of Patent: September 2, 2008Assignee: Iowa State University Research Foundation, Inc.Inventors: F. Chris Minion, Steven P. Djordjevic
-
Patent number: 7413708Abstract: An oligonucleotide probe is disclosed, the probe including an oligonucleotide, a fluorescer molecule attached to a first end of the oligonucleotide and a quencher molecule attached to the opposite end of the oligonucleotide. The probe is rendered impervious to digestion by the 5??3? exonuclease activity of a polymerase and the 5??3? extension of by a polymerase. The invention also includes methods for performing combined PCR amplification and hybridization probing, one such method including the steps of contacting a target nucleic acid sequence with PCR reagents and an oligonucleotide probe as described above, and subjecting these reagents to thermal cycling. One preferred refinement of the above method further includes the addition of a strand displacer to facilitate amplification.Type: GrantFiled: July 9, 2007Date of Patent: August 19, 2008Assignee: Applied Biosystems Inc.Inventor: Paul E. Mayrand
-
Patent number: 7407815Abstract: A functional cassette for the detection of ligands comprises a first inner housing, a second middle housing and a third outer housing and each housing is at least partially rotatable relative to an adjoining housing. The first inner housing contains a central well adapted for receiving a sample, and the central well is in selectable fluid communication with at least one mixing chambers. The mixing chambers contain a reagent for forming a complex with a ligand. The first inner housing additionally comprises at least one compartments for the storage of a liquid crystalline material, and the compartments are in selectable fluid communication with at least one mixing chambers. The third outer housing comprises at least one detection chambers for observing the light transmission properties of a liquid crystal material and the detection chambers are in selectable fluid communication with the mixing.Type: GrantFiled: September 27, 2006Date of Patent: August 5, 2008Assignees: Kent State University, Northeastern Ohio Universities College of MedicineInventors: Christopher J. Woolverton, Gary D. Niehaus
-
Patent number: 7407813Abstract: An analytical test device incorporating a dry porous carrier to which a liquid sample, eg. urine, suspected of containing an analyte such as HCG or LH can be applied indirectly, the device also incorporating a labelled specific binding reagent which is freely mobile in the porous carrier when in the moist state, and an unlabelled specific binding reagent which is permanently immobilised in a detection zone on the carrier material, the labelled and unlabelled specific binding reagents being capable of participating in either a sandwich reaction or a competition reaction in the presence of the analyte, in which prior to the application to the device of a liquid sample suspected of containing the analyte, the labelled specific binding reagent is retained in the dry state in a macroporous body, eg.Type: GrantFiled: December 23, 2002Date of Patent: August 5, 2008Assignee: Inverness Medical Switzerland GmbHInventors: Paul James Davis, Michael Evans Prior, Keith May
-
Patent number: 7408039Abstract: The inventors have discovered that hematologic disorders, e.g., both neoplastic (hematologic cancers) and non-neoplastic conditions, can be treated by the induction of mixed chimerism using myeloreductive, but not myeloablative, conditioning. Methods of the invention reduce GVHD, especially GVHD associated with mismatched allogeneic or xenogeneic donor tissue, yet provide, for example, significant graft-versus-leukemia (GVL) effect and the like.Type: GrantFiled: February 25, 2003Date of Patent: August 5, 2008Assignee: The General Hospital CorporationInventors: Megan Sykes, Thomas R. Spitzer
-
Patent number: 7396674Abstract: Reaction vessel 1 for assaying of a subject substrate molecule comprises a translucent narrow tube 2 which has a liquid feed port 4 at one end, and which is intended to be packed with microparticles 5 as solid phase support on which a reagent molecule is bound thereto, in which said reagent is capable of binding to, adsorbing, or showing affinity with the subject substrate molecule, and a effluent collecting tube 3 in which a liquid absorbing member 13 is provided inside for absorbing the liquid poured into the narrow tube, and which is connected to the narrow tube 2 at its downstream via a communicating passage 11, and a current-controlling mechanism for controlling liquid current in the narrow tube so as to hold the liquid in the narrow tube 2 during a predetermined time.Type: GrantFiled: March 22, 2007Date of Patent: July 8, 2008Assignee: Itoham Foods, Inc.Inventors: Junji Miyakawa, Asami Matsumoto, Shusaku Oka
-
Patent number: 7393530Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-1?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: July 7, 2006Date of Patent: July 1, 2008Assignee: Schering CorporationInventor: Jacqueline C. Timans
-
Patent number: 7393647Abstract: This invention pertains to methods for detecting B. anthracis and antibodies to B. anthracis, the causative agent of anthrax, in a subject.Type: GrantFiled: May 27, 2003Date of Patent: July 1, 2008Assignee: Biosite IncorporatedInventors: Gunars Edwin Valkirs, Kenneth Buechler
-
Patent number: 7390674Abstract: There is provided a lateral flow assay device for detecting the presence or quantity of an analyte residing in a test sample where the lateral flow assay device has a porous membrane in communication with a wicking pad. The porous membrane has a detection zone which has a chromophore configured to chemically react with an analyte or a secondary trigger or a reaction product from the analyte and a trigger generating reagent(s), to generate a visually detectible signal. Additional chrmophore zones may be located downstream from the first chrmophore zone to generate signals of varying color. Scavenging zones may be included between chromophore zones to attenuate the signal by reacting with the analyte without generating a visually detectable signal.Type: GrantFiled: March 14, 2005Date of Patent: June 24, 2008Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Shawn Ray Feaster, Kaiyuan Yang
-
Patent number: 7387890Abstract: An immunoassay device has a housing defining a first opening for receiving a solution and a second opening through which a liquid sample is deposited, a strip of sorbent material having a test site with immobilized antigen or antibody for the ligand to be tested, and a filter for filtering the sample. The filter is located at the second opening and directly above the test site. The sorbent material defines a horizontal flow path in the housing for the solution from the first opening to the test site. In use, the sample is first applied via the filter to the test site, and then, after the ligand has been captured, a buffer added through the first opening is used to cause a secondary specific binder conjugated to a marker to migrate horizontally by capillary action to the test site where it can bind to the already captured ligand. This immunoassay offer several advantages over the traditional chromatographic immunoassays.Type: GrantFiled: December 16, 2004Date of Patent: June 17, 2008Assignee: Chembio Diagnostic Systems, Inc.Inventor: Javanbakhsh Esfandiari
-
Patent number: 7385035Abstract: This invention relates to a new cytotoxic protein (M toxin, mucous layer devastating toxin) produced by Helicobacter pylori and the use. This invention provides a cytotoxic protein (M toxin) produced by Helicobacter pylori, a partial peptide, and an antitumor agent containing the cytotoxic protein. The protein is obtained by culturing a transformant which is transformed with a recombination vector containing DNA coding the cytotoxin protein. This invention provides further the use of the protein.Type: GrantFiled: December 5, 2002Date of Patent: June 10, 2008Assignee: Fourier Inc.Inventors: Hiroyuki Ohno, Hiromitsu Saisho, Hideki Tanzawa
-
Patent number: 7384779Abstract: A substrate plate or device adapted for use with biological or chemical assays is disclosed. The device may take the form of a multi-well plate having a three-dimensional, porous layer as part of a support surface within each well for immobilizing probe species. The porous layer is characterized as having a plurality of interconnected voids defined by a matrix of contiguous solid material. A method and its variants are also described.Type: GrantFiled: April 12, 2004Date of Patent: June 10, 2008Assignee: Corning IncorporatedInventors: Ye Fang, Ann M. Ferrie, Yulong Hong, Brian L. Webb
-
Patent number: 7384796Abstract: An analytical test device incorporating a dry porous carrier to which a liquid sample, eg. urine, suspected of containing an analyte such as HCG or LH can be applied indirectly, the device also incorporating a labelled specific binding reagent which is freely mobile in the porous carrier when in the moist state, and an unlabelled specific binding reagent which is permanently immobilised in a detection zone on the carrier material, the labelled and unlabelled specific binding reagents being capable of participating in either a sandwich reaction or a competition reaction in the presence of the analyte, in which prior to the application to the device of a liquid sample suspected of containing the analyte, the labelled specific binding reagent is retained in the dry state in a macroporous body, eg.Type: GrantFiled: December 23, 2002Date of Patent: June 10, 2008Assignee: Inverness Medical Switzerland GmbHInventors: Paul James Davis, Michael Evans Prior, Keith May
-
Patent number: 7381534Abstract: Disclosed are major allergenic proteins in cashew nut, which are legumin-like proteins and 2S albumins. Also disclosed is a polypeptide allergen in the 7S superfamily, which includes vicilin-like and sucrose binding proteins. Several linear epitopes of the cashew nut are identified and characterized. The invention further discloses the sequence of cDNA encoding the allergenic polypeptide, the allergen being designated Ana o 1, and also describes the characterization of the expressed recombinant polypeptide and associated methods employing the polypeptide.Type: GrantFiled: April 1, 2005Date of Patent: June 3, 2008Assignee: Florida State University Research Foundation, Inc.Inventors: Kenneth H. Roux, Shridhar K. Sathe, Suzanne S. Teuber
-
Patent number: 7381563Abstract: The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patents that have received allogenic bone marrow transplants.Type: GrantFiled: July 11, 2002Date of Patent: June 3, 2008Assignee: University of Southern CaliforniaInventor: David A. Horwitz
-
Patent number: 7374950Abstract: An immunochemical assay device for determining the presence of NT-proBNP alone or conjunctively with Cardiac Troponin I comprising a base member, an array disposed on the base member, and at least one assay indicia zone. The array comprises (i) a reservoir pad to receive sample liquid, (ii) a wicking membrane, and (iii) at least one filter zone interposed between the wicking membrane and the reservoir pad. The filter zone being operable to permit passage of any specific immunocomplex to the wicking membrane while impeding passage of larger components.Type: GrantFiled: September 28, 2006Date of Patent: May 20, 2008Assignee: Princeton Biomeditech CorporationInventors: Jemo Kang, Kyung-ah Kim, Joo Young Choi, George Jackowski
-
Patent number: 7371583Abstract: Disclosed is a testing device and methods for the identification of an analyte of interest in a sample. In a preferred embodiment, the testing device includes a front panel having at least one sample application aperture; a rear panel having at least one solvent application aperture; a sample collection matrix disposed between the rear panel and the front panel, the sample collection matrix being in communication with the sample and solvent application apertures of the front and rear panels; and at least one insertable test strip containing a reagent enabling detection of the analyte of interest.Type: GrantFiled: March 11, 2005Date of Patent: May 13, 2008Assignee: Enterix, Inc.Inventor: Howard Chandler
-
Patent number: 7371526Abstract: The invention provides methods and materials for conversion of cytosine to uracil. In some embodiments, a nucleic acid, such as gDNA, is reacted with at least one bisulfite salt having the formula X+HSO3? or Y+2(HSO331)2; wherein X+ is ammonium ion, a tetraalkyl ammonium ion, or a group 1A ion other than sodium; and Y+2 is a group 2A ion or a group 7B ion; under conditions effective to convert at least one cytosine nucleobase to a uracil nucleobase. In some embodiments, X+ comprises at least one of lithium ion, potassium ion, ammonium ion, tetraalkylammonium ion, magnesium ion, manganese ion and calcium ion. In some embodiments, the reacting is performed optionally in the presence of a polyamine catalyst and/or a quaternary amine catalyst. Also provided are kits that can be used to carry out methods of the invention.Type: GrantFiled: August 26, 2004Date of Patent: May 13, 2008Assignee: Applera CorporationInventors: Gerald Zon, Victoria L. Boyd
-
Patent number: 7361462Abstract: The present invention is directed to directly measure distribution in vivo and the frequency of generation in vivo of DNA strand breaks which induce cell death and mutations. The present inventors accomplished the present invention by providing a method for detecting a DNA strand break in a sample, which comprises a step of binding a PprA protein derived from Deinococcus radiodurans to a DNA strand break and a step of detecting the PprA protein which is bound to the DNA strand break; as well as by providing a kit for detecting a DNA strand break in a sample which comprises PprA proteins derived from Deinococcus radiodurans and a means for detecting a PprA protein which is bound to a DNA strand break.Type: GrantFiled: September 17, 2003Date of Patent: April 22, 2008Assignee: Japan Atomic Energy Research InstituteInventors: Katsuya Satoh, Seiichi Wada, Issay Narumi, Masahiro Kikuchi, Tomoo Funayama, Yasuhiko Kobayashi
-
Patent number: 7358099Abstract: Superparamagnetic (“SPM”) subunits of 1–30 nm average mean diameter (e.g. ferro fluid) subparticles are treated with a magnetically noninterfering substance capable of coating and covering them (e.g, BSA) and they spontaneously form agglomerates of about 100 nm to about 450 nm or higher average mean diameter and are then used to form complexes with target biological ligands such as viruses, contained in large volumes of liquid. The complexes are subjected to the gradient intensity of a strong magnetic field, and excess liquid is removed, where upon an immunochromatographic assay is conducted to determine the identity and/or amount of target ligand present, in which operation SPM particles that bonded to the ligand function as tags for ligand detection.Type: GrantFiled: December 7, 2005Date of Patent: April 15, 2008Assignee: Binax, Inc.Inventors: Roger N. Piasio, Nathan Turner
-
Patent number: 7345046Abstract: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.Type: GrantFiled: May 21, 2004Date of Patent: March 18, 2008Assignee: Chiron CorporationInventors: Weibo Wang, Liana Marie Lagniton, Ryan N. Constantine, Matthew T. Burger
-
Patent number: 7344878Abstract: A sterile housing for the cultivation of micro-organisms has a container closed by a cover with a culture medium within the walls and base. The cover has a bottom forming a base and walls connected to the bottom, and the lid is set on the container and includes a peripheral sealing zone having a flat section recessed relative to the bottom of the container. A concave inner seal is fixed to the peripheral sealing zone of the lid to hermetically seal the box by enclosing the container, enabling the inner seal to be removed without exposing the culture medium.Type: GrantFiled: January 10, 2002Date of Patent: March 18, 2008Assignee: Developpement Techniques Plastiques Holding (D.T.P. Holding)Inventor: Jean Lemonnier
-
Patent number: 7329536Abstract: An apparatus comprising one or more piezoelectric mass sensors for use in diagnostic and analytic processes, in particular for immunochemical detection of diagnostically relevant analytes in real time, is described. Each piezoelectric mass sensor comprises a piezoelectric crystal with a receptor surface which has immobilized thereon a lawn of recombinant antibodies comprising single VH chain or single-chain Fv (scFv) polypeptides specific for a particular antigen. Binding of antigen to the recombinant antibodies results in a change in mass on the receptor surface which is detected as a change in resonant frequency. In a preferred embodiment, the receptor layer is a precious metal such as gold which facilitates self-assembly of the recombinant antibodies into a lawn on the receptor surface via a cysteine residue at the carboxy terminus of the attachment polypeptide.Type: GrantFiled: June 4, 2004Date of Patent: February 12, 2008Assignees: Oakland University, Vanderbilt UniversityInventors: Xiangqun Zeng, Gabrielle Stryker, Raymond L. Mernaugh
-
Patent number: 7326578Abstract: It has been found that a urine test for ovarian reserve can be provided which is equivalent in sensitivity to current laboratory methods which determine ovarian reserve based on FSH levels in serum. A lateral flow device for indicating ovarian reserve is disclosed. The device has an application zone for receiving a urine sample, a labelling zone containing label which binds to FSH in the sample, and a detection zone where FSH-bound label is retained. The detection zone has a threshold value which corresponds to a serum FSII level of between 5-20 mIU/ml (e.g. 10 mIU/ml). A test result above the threshold value indicates diminished ovarian reserve.Type: GrantFiled: February 14, 2002Date of Patent: February 5, 2008Assignee: Genosis (UK) LimitedInventors: Paul North Bateman, Simon John Rattle
-
Patent number: 7320962Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.Type: GrantFiled: January 20, 2004Date of Patent: January 22, 2008Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Cary J. Reich, A. Edward Osawa, Helen Tran
-
Patent number: 7319032Abstract: The present invention provides methods, compositions, and kits for rapid detection of analytes in a sample. Surprisingly, it has been found that bulking materials having non-sugar sweeteners effectively enhance chromatographic detection methods by providing component stability and controlled release. Thus, the novel components and methods disclosed herein provide a completely new modality of chromatographic analyte detection.Type: GrantFiled: September 21, 2004Date of Patent: January 15, 2008Assignee: MedToxInventors: Robert Bohannon, Glen Chapman, Alan Morris, Maria Scholz-Steele, Martin Green, Phillip Hartzog, Oluyomi Adeneye
-
Patent number: 7319017Abstract: An in vitro method for identifying subjects at risk of heart failure following a Myocardial Infarction comprising analyzing the concentration of Matrix Metalloproteinase-9 in a bodily sample from a subject who has suffered a Myocardial Infarction and comparing this concentration with a reference for concentrations of Matrix Metalloproteinase-9 in individuals who have not suffered a Myocardial Infarction; wherein a raised concentration of Matrix Metalloproteinase-9 in the bodily sample from a subject who has suffered a Myocardial Infarction suggests the subject is at risk of heart failure.Type: GrantFiled: July 13, 2005Date of Patent: January 15, 2008Assignee: Centre de Recherche Public de la SantéInventor: Daniel R. Wagner
-
Patent number: 7319141Abstract: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel human stem cell growth factor-like protein. These polynucleotides comprise nucleic acid sequences isolated from cDNA libraries from human testis cells (Hyseq clone identification numbers 2880984 and 2881695), from human fetal skin (Hyseq clone identification number 15375176), adult spleen (Hyseq clone identification number 14856094), and human endothelial cells (Hyseq clone identification numbers 13804756, 13687487, 13804756). Other aspects of the invention include vectors containing processes for producing novel human stem cell growth factor-like polypeptides, and antibodies specific for such polypeptides.Type: GrantFiled: October 19, 2004Date of Patent: January 15, 2008Assignees: Kirin Beer Kabushiki Kaisha, Nuvelo, Inc.Inventors: Y. Tom Tang, Ivan Labat, Radoje T. Drmanac, Nancy K. Mize, Mitsuo Nishikawa, Cheng-Chi Chao
-
Patent number: 7309611Abstract: A test strip and method for detecting an analyte present in a sample.Type: GrantFiled: June 14, 2004Date of Patent: December 18, 2007Assignee: Relia Diagnostic Systems, LLCInventors: Robert K. DiNello, Alan J. Polito, Stella S. Quan
-
Patent number: 7309779Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.Type: GrantFiled: June 2, 2006Date of Patent: December 18, 2007Assignee: Bristol-Myers Squibb CompanyInventors: John N. Feder, Shujian Wu, Thomas C. Nelson, Liana M. Lee
-
Patent number: 7288250Abstract: In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.Type: GrantFiled: September 10, 2004Date of Patent: October 30, 2007Assignee: Critical Therapeutics, Inc.Inventors: Walter Newman, Shixin Qin, Theresa L. O'Keefe, Robert A. Obar
-
Patent number: 7288381Abstract: The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs and whole Ig for, inter alia, diagnosis, therapy and prevention of type I allergy.Type: GrantFiled: December 21, 2001Date of Patent: October 30, 2007Assignee: Phadia ABInventors: Sabine Flicker, Peter Steinberger, Dietrich Kraft, Rudolf Valenta
-
Patent number: 7285425Abstract: A device for evaluating at least one analyte in a test sample. The device comprises a cassette having a hollow test chamber, a test strip disposed within the test chamber for receiving the test sample, and a temperature control member. The cassette has at least one aperture extending from an exterior of the cassette to the hollow test chamber. The test strip includes a reagent adapted to react with the at least one analyte to produce a reaction indicative of the presence of the analyte. The temperature control member is adapted to extend through the at least one aperture in the cassette and into the test chamber for controlling the temperature of the test chamber.Type: GrantFiled: May 14, 2002Date of Patent: October 23, 2007Assignee: Siemens Medical Solutions DiagnosticsInventors: Nazeer H. Shareef, James E. Smous, James P. Albarella
-
Patent number: 7285426Abstract: The present invention provides methods, compositions, and kits for rapid detection of analytes in a sample. Surprisingly, it has been found that bulking materials having starch reagents effectively enhance chromatographic detection methods by providing component stability and controlled release. Thus, the novel components and methods disclosed herein provide a completely new modality of chromatographic analyte detection.Type: GrantFiled: May 5, 2005Date of Patent: October 23, 2007Assignee: Medtox Scientific, Inc.Inventors: Robert Bohannon, Glen Chapman, Alan Morris, Maria Scholz-Steele, Martin Green, Phillip Hartzog, Oluyomi Adeneye
-
Patent number: 7282223Abstract: This invention relates to a nutritional kit for use in preparing an individual for a predetermined activity which requires a clean digestive tract, particularly the colon. Such predetermined activities include, but are not limited to, gastrointestinal surgery and colon screenings. Specifically, the present invention provides an individual low amounts of fat, dietary fiber and solid food content to minimize stool formation and/or facilitate removal of stool from the digestive tract prior to the predetermined activity. The present invention also provides the individual with sufficient calories and nutrition to enable the individual to conduct daily, routine activities while utilizing the present invention.Type: GrantFiled: August 10, 2004Date of Patent: October 16, 2007Assignee: E-Z-EM, Inc.Inventor: Howard S. Stern
-
Patent number: 7279548Abstract: Novel polypeptides having WW domains of interest are described, along with DNA sequences that encode the same. A method of identifying these polypeptides by means of a sequence-independent (that is, independent of the primary sequence of the polypeptide sought), recognition unit-based functional screen is also disclosed. Various applications of the method and of the polypeptides identified are described, including their use in assay kits for drug discovery, modification, and refinement.Type: GrantFiled: June 28, 2002Date of Patent: October 9, 2007Assignees: Cytogen Corporation, The University of North Carolina at Chapel HillInventors: Gregorio Pirozzi, Brian K. Kay, Dana M. Fowlkes
-
Patent number: 7276362Abstract: The invention relates to a modified IMPDH polypeptide wherein the IMPDH polypeptide has a histidine tag and where the subdomain of the IMPDH polypeptide is modified so that the rate stability of the histidine-tagged, modified IMPDH polypeptide is maintained relative to the wild-type IMPDH polypeptide. The invention also relates to a method, nucleic acid molecules, vectors, and host cells for producing such a histidine-tagged, modified IMPDH polypeptide, and to kits comprising the histidine-tagged, modified IMPDH polypeptide.Type: GrantFiled: January 30, 2004Date of Patent: October 2, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Allan R. Dorn, Janice E. Rugaber
-
Patent number: 7270816Abstract: Nucleic acids encoding mammalian, e.g., primate, IL-1?, purified IL-1? polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.Type: GrantFiled: October 27, 2003Date of Patent: September 18, 2007Assignee: Schering CorporationInventor: Jacqueline C. Timans
-
Patent number: 7267994Abstract: The present invention provides compositions and methods for detecting, analyzing, and identifying biomolecules. More particularly, the invention provides Element Coded Affinity Tags comprising a metal chelate and a metal ion and methods of using the tags to detect, analyze, and identify biomolecules including polypeptides, nucleic acids, lipids, and polysaccharides.Type: GrantFiled: May 24, 2004Date of Patent: September 11, 2007Assignee: Regents of the University of CaliforniaInventors: Claude F. Meares, Carlito B. Lebrilla, Nathaniel G. Butlin, Sarah M. Cheal, Todd M. Corneillie, Susan Lee, Paul A. Whetstone, Nicolas L. Young
-
Patent number: 7258989Abstract: The present invention relates to antibodies which, in agueous solution, selectively bind to a transferrin-homologous carbohydrate deficient transferrin (CDT) without the latter needing to be bound to a solid phase. CDT is characterized by at least one of the two oligosaccharide chains which are normally bound to Asn 413 and/or Asn 611 of transferrin being entirely or substantially entirely lacking.Type: GrantFiled: July 3, 2003Date of Patent: August 21, 2007Assignee: Dade Behring Marburg GmbHInventor: Harald Althaus
-
Patent number: 7256037Abstract: Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL-response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and/or CpG oligodeoxynucleotide immunomodulators.Type: GrantFiled: December 23, 2003Date of Patent: August 14, 2007Assignee: City of HopeInventors: Joshua D. I. Ellenhorn, Don J. Diamond
-
Patent number: 7256275Abstract: This invention pertains to the field of combination oligomers, including the block synthesis of combination oligomers in the absence of a template, as well as related methods, kits, libraries and other compositions.Type: GrantFiled: March 9, 2002Date of Patent: August 14, 2007Assignee: Boston Probes, Inc.Inventors: James M. Coull, Mark J. Fiandaca, Mark D. Kristjanson, Jens J. Hyldig-Nielsen, Theresa S. Creasey
-
Patent number: 7253008Abstract: Disclosed herein are substrates comprising reactive ion etched surfaces and specific binding agents immobilized thereon. The substrates may be used in methods and devices for assaying or isolating analytes in a sample. Also disclosed are methods of making the reactive ion etched surfaces.Type: GrantFiled: December 28, 2004Date of Patent: August 7, 2007Assignee: Sandia CorporationInventors: Victor C. Rucker, Renée Shediac, Blake A. Simmons, Karen L. Havenstrite
-
Patent number: 7250308Abstract: Device (1) for assaying a particulate analyte, comprising (a) a receptacle (2) for receiving a suspension (5) of particulate analyte, and containing label (3) for the particulate analyte, and (b) a porous detection material (4) that is permeable to label (3) but is impermeable to particulate analyte, the detection material (4) being arranged within receptacle (2) such that introduction of suspension (5) of particulate analyte into receptacle (2) forms liquid communication between label (3) and detection material (4). After liquid sample (5) is introduced into the receptacle (2), capillary flow through the porous detection material (4) begins. Particulate analyte cannot flow through the detection material (4) and is captured at its surface. Addition of liquid sample (5) also releases the label (3) within the receptacle (2), which is then free to flow through the detection material (4). Label (3) encounters the captured analyte and gives a signal (7).Type: GrantFiled: April 2, 2001Date of Patent: July 31, 2007Assignee: Genosis (UK) LimitedInventor: Karen Whiting
-
Patent number: 7247469Abstract: Arrays of protein-capture agents useful for the simultaneous detection of a plurality of proteins which are the expression products, or fragments thereof, of a cell or population of cells in an organism are provided. A variety of antibody arrays, in particular, are described. Methods of both making and using the arrays of protein-capture agents are also disclosed. The invention arrays are particularly useful for various proteomics applications including assessing patterns of protein expression and modification in cells.Type: GrantFiled: May 24, 2005Date of Patent: July 24, 2007Assignee: Zyomyx, Inc.Inventors: Peter Wagner, Peter Kernen, Hongbo Lu, Huu Tran
-
Patent number: 7241418Abstract: The invention concerns a method for the detection of an analyte in a sample using analyte-specific conjugates which have at least one heterologous group for an analyte-independent binding to a control zone. The present invention additionally provides new conjugates and reagent kits.Type: GrantFiled: July 1, 2005Date of Patent: July 10, 2007Assignee: Roche Diagnostics CorporationInventors: Jurgen Schaffler, Barbara Upheimer
-
Patent number: 7238537Abstract: An analytical test device incorporating a dry porous carrier to which a liquid sample, eg. urine, suspected of containing an analyte such as HCG or LH can be applied indirectly, the device also incorporating a labelled specific binding reagent which is freely mobile in the porous carrier when in the moist state, and an unlabelled specific binding reagent which is permanently immobilized in a detection zone on the carrier material, the labelled and unlabelled specific binding reagents being capable of participating in either a sandwich reaction or a competition reaction in the presence of the analyte, in which prior to the application to the device of a liquid sample suspected of containing the analyte, the labelled specific binding reagent is retained in the dry state in a macroporous body, eg.Type: GrantFiled: September 4, 2001Date of Patent: July 3, 2007Assignee: Inverness Medical Switzerland GmbHInventors: Paul James Davis, Michael Evans Prior, Keith May
-
Patent number: 7238538Abstract: A chromatographic assay device for the analysis of an analyte in a liquid sample has a proximal sample application zone and a distal test zone. The test zone contains a first ligand capable of binding with the analyte to form an analyte-ligand complex. The device also includes a spatially distinct reservoir containing a labeled reagent capable of binding to the analyte-ligand complex; an absorbent sink which is positioned to be capable of drawing the contents of the spatially distinct reservoir through the test zone; and structures for contacting the spatially distinct reservoir with the chromatographic medium so that the labeled reagent migrates from the reservoir to the absorbent sink, and thereby through the test zone to determine the presence or absence of the analyte. The device is used in a method for detecting analyte.Type: GrantFiled: September 16, 2004Date of Patent: July 3, 2007Inventors: Helmut E. Freitag, Qinwei Shi
-
Patent number: 7238519Abstract: An immunoassay cassette, apparatus, and method for detecting an analyte in a liquid body-fluid sample are disclosed. The cassette has a body and a support mounted on the body, for movement relative to the body to first and second transfer positions. Sample supplied to a sample well in the cassette body is transferred to a reagent reservoir on the cassette body, by moving the support to its first transfer position. Here the sample reacts with a first reagent composition in the reservoir effective to form a modified sample. The modified sample is then transferred to a reagent strip on the support by moving the support to its second transfer position. The reagent strip has a transfer zone at which sample material is transferred to the strip, a second reagent composition effective to react with the modified sample to form a detectable analyte-dependent product, and a detection zone located downstream at which the detectable product can be observed.Type: GrantFiled: December 17, 2004Date of Patent: July 3, 2007Assignee: Cholestech CorporationInventors: Neal F. Bellet, Jeffrey Shindelman, Thomas E. Worthy, Kimberly Haley, Richard K-T Lee, Jane Eunhee Kyung, Suyue Qian
-
Patent number: 7235370Abstract: A method of making a derivatized aminoglycoside includes reacting an aminoglycoside with at least 2 equivalents of a divalent metal ion in an aprotic solvent to complex two neighboring amino group and hydroxyl group pairs; reacting the non-complexed amino groups with a protecting reagent to provide protecting groups; removing the divalent metal ion to provide two unprotected amino groups; reacting one of the unprotected amino groups with a reactive substance containing an linker, a carrier, or a label; and removing the protecting groups. This method can be used to produce novel compounds and reagents.Type: GrantFiled: July 22, 2003Date of Patent: June 26, 2007Assignee: Roche Diagnostics Operations, Inc.Inventors: Mitali Ghoshal, Salvatore J. Salamone